Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.16 USD | +9.85% | +8.86% | -46.43% |
May. 15 | Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 22 | HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating | MT |
Evolution of the average Target Price on Cabaletta Bio, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Cabaletta Bio, Inc.
HC Wainwright | |
Jefferies & Co. | |
Morgan Stanley | |
Cantor Fitzgerald | |
Stifel Nicolaus | |
Wells Fargo Securities | |
Citigroup | |
Guggenheim | |
Chardan Research | |
Mizuho Securities | |
Evercore ISI | |
Chardan |
EPS Revisions
- Stock Market
- Equities
- CABA Stock
- Consensus Cabaletta Bio, Inc.